EPIX Pharm completes trials enrollment
Massachusetts, USA-based EPIX Pharmaceuticals says that it has met its enrollment target of 330 patients in US centers for its Phase IIb trial of PRX-00023 in major depressive disorder. As a result, the firm expects to announce the findings of this trial in the first quarter of 2008.
Furthermore, EPIX has completed enrollment of its Phase IIa study of PRX-03140 in Alzheimer's disease and reaffirmed that it is on track to announce the results of this by the end of 2007.
Michael Kauffman, chief executive of EPIX, said: "we believe that the rapid pace at which we were able to recruit patients into the Phase IIb MDD trial is indicative of the interest in, and need for, new and improved treatments for depression."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze